Bivalent molecular probes for dopamine D2-like receptors
摘要:
Merging two arylamidoalkyl substituted phenylpiperazines as prototypical recognition elements for dopamine D-2-like receptors by oligoethylene glycol linkers led to a series of bivalent ligands. These dimers were investigated in comparison to their monomeric analogues for their dopamine D-2long, D-2short, D-3 and D-4 receptor binding. Radioligand binding experiments revealed strong bivalent effects for some para-substituted benzamide derivatives. For the D-3 subtype, the target compounds 32, 34 and 36 showed an up to 70-fold increase of affinity and a substantial enhancement of subtype selectivity when compared to the monovalent analogue 24. Analysis of the binding curves displayed Hill slopes very close to one indicating that the bivalent ligands displace 1 equiv of radioligand. Obviously, the two pharmacophores occupy an orthosteric and an allosteric binding site rather than adopting a receptor-bridging binding mode. (C) 2011 Elsevier Ltd. All rights reserved.
Bivalent molecular probes for dopamine D2-like receptors
摘要:
Merging two arylamidoalkyl substituted phenylpiperazines as prototypical recognition elements for dopamine D-2-like receptors by oligoethylene glycol linkers led to a series of bivalent ligands. These dimers were investigated in comparison to their monomeric analogues for their dopamine D-2long, D-2short, D-3 and D-4 receptor binding. Radioligand binding experiments revealed strong bivalent effects for some para-substituted benzamide derivatives. For the D-3 subtype, the target compounds 32, 34 and 36 showed an up to 70-fold increase of affinity and a substantial enhancement of subtype selectivity when compared to the monovalent analogue 24. Analysis of the binding curves displayed Hill slopes very close to one indicating that the bivalent ligands displace 1 equiv of radioligand. Obviously, the two pharmacophores occupy an orthosteric and an allosteric binding site rather than adopting a receptor-bridging binding mode. (C) 2011 Elsevier Ltd. All rights reserved.
[EN] MODULATORS OF HEMOGLOBIN FOR THE TREATMENT OF SICKLE CELL DISEASE<br/>[FR] MODULATEURS DE L'HÉMOGLOBINE POUR LE TRAITEMENT DE LA DRÉPANOCYTOSE
申请人:GLOBAL BLOOD THERAPEUTICS INC
公开号:WO2020072377A1
公开(公告)日:2020-04-09
The present disclosure relates to compounds of the general formula (I) and pharmaceutical compositions containing them. The compounds are suitable as modulators of hemoglobin and thus useful in treating disorders mediated by hemoglobin such as sickle cell disease.
HYPERTHEROMOSTABLE ENDONUCLEASE IV SUBSTRATE PROBE
申请人:Belousov Yevgeniy
公开号:US20110151457A1
公开(公告)日:2011-06-23
The present invention relates to a hyperthermostable endonuclease IV substrate probe to be used in nucleic acid assay methods which can be carried out using hyperthermostable enzymes, including detection of target nucleic acids, and detection of nucleic acid polymorphism.
The present invention relates to a hyperthermostable endonuclease IV substrate probe to be used in nucleic acid assay methods which can be carried out using hyperthermostable enzymes, including detection of target nucleic acids, and detection of nucleic acid polymorphism.
MODULATORS OF HEMOGLOBIN FOR THE TREATMENT OF SICKLE CELL DISEASE
申请人:Global Blood Therapeutics, Inc.
公开号:EP3860975A1
公开(公告)日:2021-08-11
[EN] HYPERTHEROMOSTABLE ENDONUCLEASE IV SUBSTRATE PROBE<br/>[FR] SONDE DE SUBSTRAT DE L'ENDONUCLÉASE IV HYPERTHERMOSTABLE
申请人:ELITECH HOLDING BV
公开号:WO2011087707A1
公开(公告)日:2011-07-21
The present invention relates to a hyperthermostable endonuclease IV substrate probe to be used in nucleic acid assay methods which can be carried out using hyperthermostable enzymes, including detection of target nucleic acids, and detection of nucleic acid polymorphism.